Thyrocare Technologies Ltd
NSE:THYROCARE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Y
|
Yamana Gold Inc
LSE:AUY
|
CA |
|
Brouwerij - Handelsmaatschappij NV
XBRU:COBH
|
BE |
|
Mativ Holdings Inc
NYSE:MATV
|
US |
|
Alice Queen Ltd
ASX:AQX
|
AU |
|
Arthur J Gallagher & Co
NYSE:AJG
|
US |
|
CURRENC Group Inc
NASDAQ:CURR
|
SG |
|
Orascom Development Holding AG
SIX:ODHN
|
CH |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
58.2B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
93.4B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
67.2B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
71.1B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
24.5B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.5B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.5B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.3B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10B USD |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Thyrocare Technologies Ltd is 23.5%, which is above its 3-year median of 17.9%.
Over the last 3 years, Thyrocare Technologies Ltd’s Operating Margin has increased from 18.3% to 23.5%. During this period, it reached a low of 14.7% on Jun 30, 2023 and a high of 23.5% on Jan 1, 2026.
